When do you consider the use of JAK inhibitors for cutaneous manifestations of myositis?

JAK inhibitors have been shown to be effective especially for skin manifestations in dermatomyositis in an open-label trial (Paik et al., PMID 33258553). However, given the limitations imposed by insurance companies, I consider JAK inhibitors most commonly in the following scenarios:

1. when the patien...